RapidPulse Closes $15 Million Series A Financing

RapidPulse Inc., a privately-held medical device company developing an aspiration system to treat ischemic stroke, has closed a $15 million Series A financing. The financing was led by Santé Ventures, which was joined by Epidarex Capital, Hatteras Venture Partners, Broadview Ventures, and Syntheon. RapidPulse plans to use the proceeds to advance its RapidPulse Cyclic Aspiration System through expanded clinical evaluation and build out its platform of proprietary catheters.
 
The RapidPulse system was developed by Syntheon, a medical device incubator focused on developing next generation medical devices. Their various products, commercialized by the largest and most trusted medical device companies in the world, have treated over 50 million patients globally in applications ranging from laparoscopic surgery, cardiovascular, and flexible endoscopy. Syntheon has over 200 issued patents since its inception over 20 years ago.
 
“We are pleased to have partnered with an outstanding investor syndicate to move our RapidPulse technology forward in the clinic,” said Sean McBrayer, CEO of Syntheon, who will also serve as initial CEO of RapidPulse. “Stroke is the second leading cause of death and the third leading cause of disability worldwide, and minutes matter in improving these outcomes. This investment will help us expand our clinical results and move towards regulatory approval in the United States.”
 
Joining the team are industry veterans Heather Harries and Cynthia Yang. Harries most recently served as general manager for Terumo’s aortic business and will lead product development and operations for RapidPulse. Yang will lead clinical development for the company, after most recently working in the neurovascular division of Medtronic plc.
 
Dennis McWilliams, partner at Santé Ventures, added, “Heather and Cynthia bring exceptional domain expertise to the team at RapidPulse, and will complement the significant engineering development experience at Syntheon. RapidPulse is a disruptive platform opportunity in neurovascular, and has the potential to significantly improve patient outcomes for ischemic stroke patients.”
 
RapidPulse Inc. is a privately held medical device company that develops minimally invasive vascular products for ischemic stroke. The company is advancing the development of the RapidPulse Cyclic Aspiration System, which includes a novel aspiration pump to allow rapid and consistent removal of blood clots from the brain. RapidPulse is a spinout of Syntheon LLC., a medical device incubator dedicated to developing innovative products in the medical device industry.